4'-Deoxydoxorubicin (esorubicin) in non-Hodgkin's lymphomas and plasma cell tumors: First evidence of activity

V. Zagonel, U. Tirelli, R. Sorio, S. Frustaci, M. A. Pacciarini, N. Di Pietro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

From May, 1984 to December, 1985, 30 patients, 10 of them with non-Hodgkins lymphoma (NHL) and 20 with plasma-cell tumors (PCT) (19 multiple myeloma and 1 Waldenstrm's macroglobulinemia), entered two phase II studies with 4'-deoxydoxorubicin (esorubicin): 30 mg/m2 i.v. every three weeks, with an increase to 35 mg/m2 when bone marrow toxicity was absent after the first cycle, for at least two or three cycles prior to evaluation. The 25 evaluable patients received a median number of 3 courses of esorubicin (range 1-14). Among the 9 evaluable patients with NHL, 3 (33%) obtained CR and 2 (22%) PR for an overall 55% objective response rate. Two of the patients with CR had been previously treated with doxorubicin. Duration of response was short (9, 13, 14 weeks, respectively). No response was seen in 2 patients with Mycosis Fungoides. Among the 16 evaluable patients with PCT, 2 (12.5%) obtained a response, and 4 (25%) obtained improvement. None of these patients was previously treated with doxorubicin. Toxicity according to criteria proposed by WHO was acceptable in patients with NHL, whereas it was quite severe in patients with PCT, with two deaths from septicemia during the granulocytopenic periods. Congestive heart failure and change in the left ventricular ejection fraction were not evidenced in any patient, in particular not in the patient who has been treated with 14 cycles of esorubicin for a total dose of 300 mg/m2. Although preliminary, our results have shown that esorubicin is capable of inducing a consistent proportion of objective responses in patients with NHL and PCT, even in those previously treated and resistant to doxorubicin.

Original languageEnglish
Pages (from-to)97-99
Number of pages3
JournalHaematologica
Volume72
Issue number1
Publication statusPublished - 1987

Fingerprint

Plasmacytoma
Non-Hodgkin's Lymphoma
Doxorubicin
esorubicin
Waldenstrom Macroglobulinemia
Mycosis Fungoides
Multiple Myeloma
Stroke Volume
Sepsis
Heart Failure
Bone Marrow

ASJC Scopus subject areas

  • Hematology

Cite this

4'-Deoxydoxorubicin (esorubicin) in non-Hodgkin's lymphomas and plasma cell tumors : First evidence of activity. / Zagonel, V.; Tirelli, U.; Sorio, R.; Frustaci, S.; Pacciarini, M. A.; Di Pietro, N.

In: Haematologica, Vol. 72, No. 1, 1987, p. 97-99.

Research output: Contribution to journalArticle

Zagonel, V. ; Tirelli, U. ; Sorio, R. ; Frustaci, S. ; Pacciarini, M. A. ; Di Pietro, N. / 4'-Deoxydoxorubicin (esorubicin) in non-Hodgkin's lymphomas and plasma cell tumors : First evidence of activity. In: Haematologica. 1987 ; Vol. 72, No. 1. pp. 97-99.
@article{2b46071c6974407d94034f146edbf8cf,
title = "4'-Deoxydoxorubicin (esorubicin) in non-Hodgkin's lymphomas and plasma cell tumors: First evidence of activity",
abstract = "From May, 1984 to December, 1985, 30 patients, 10 of them with non-Hodgkins lymphoma (NHL) and 20 with plasma-cell tumors (PCT) (19 multiple myeloma and 1 Waldenstrm's macroglobulinemia), entered two phase II studies with 4'-deoxydoxorubicin (esorubicin): 30 mg/m2 i.v. every three weeks, with an increase to 35 mg/m2 when bone marrow toxicity was absent after the first cycle, for at least two or three cycles prior to evaluation. The 25 evaluable patients received a median number of 3 courses of esorubicin (range 1-14). Among the 9 evaluable patients with NHL, 3 (33{\%}) obtained CR and 2 (22{\%}) PR for an overall 55{\%} objective response rate. Two of the patients with CR had been previously treated with doxorubicin. Duration of response was short (9, 13, 14 weeks, respectively). No response was seen in 2 patients with Mycosis Fungoides. Among the 16 evaluable patients with PCT, 2 (12.5{\%}) obtained a response, and 4 (25{\%}) obtained improvement. None of these patients was previously treated with doxorubicin. Toxicity according to criteria proposed by WHO was acceptable in patients with NHL, whereas it was quite severe in patients with PCT, with two deaths from septicemia during the granulocytopenic periods. Congestive heart failure and change in the left ventricular ejection fraction were not evidenced in any patient, in particular not in the patient who has been treated with 14 cycles of esorubicin for a total dose of 300 mg/m2. Although preliminary, our results have shown that esorubicin is capable of inducing a consistent proportion of objective responses in patients with NHL and PCT, even in those previously treated and resistant to doxorubicin.",
author = "V. Zagonel and U. Tirelli and R. Sorio and S. Frustaci and Pacciarini, {M. A.} and {Di Pietro}, N.",
year = "1987",
language = "English",
volume = "72",
pages = "97--99",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - 4'-Deoxydoxorubicin (esorubicin) in non-Hodgkin's lymphomas and plasma cell tumors

T2 - First evidence of activity

AU - Zagonel, V.

AU - Tirelli, U.

AU - Sorio, R.

AU - Frustaci, S.

AU - Pacciarini, M. A.

AU - Di Pietro, N.

PY - 1987

Y1 - 1987

N2 - From May, 1984 to December, 1985, 30 patients, 10 of them with non-Hodgkins lymphoma (NHL) and 20 with plasma-cell tumors (PCT) (19 multiple myeloma and 1 Waldenstrm's macroglobulinemia), entered two phase II studies with 4'-deoxydoxorubicin (esorubicin): 30 mg/m2 i.v. every three weeks, with an increase to 35 mg/m2 when bone marrow toxicity was absent after the first cycle, for at least two or three cycles prior to evaluation. The 25 evaluable patients received a median number of 3 courses of esorubicin (range 1-14). Among the 9 evaluable patients with NHL, 3 (33%) obtained CR and 2 (22%) PR for an overall 55% objective response rate. Two of the patients with CR had been previously treated with doxorubicin. Duration of response was short (9, 13, 14 weeks, respectively). No response was seen in 2 patients with Mycosis Fungoides. Among the 16 evaluable patients with PCT, 2 (12.5%) obtained a response, and 4 (25%) obtained improvement. None of these patients was previously treated with doxorubicin. Toxicity according to criteria proposed by WHO was acceptable in patients with NHL, whereas it was quite severe in patients with PCT, with two deaths from septicemia during the granulocytopenic periods. Congestive heart failure and change in the left ventricular ejection fraction were not evidenced in any patient, in particular not in the patient who has been treated with 14 cycles of esorubicin for a total dose of 300 mg/m2. Although preliminary, our results have shown that esorubicin is capable of inducing a consistent proportion of objective responses in patients with NHL and PCT, even in those previously treated and resistant to doxorubicin.

AB - From May, 1984 to December, 1985, 30 patients, 10 of them with non-Hodgkins lymphoma (NHL) and 20 with plasma-cell tumors (PCT) (19 multiple myeloma and 1 Waldenstrm's macroglobulinemia), entered two phase II studies with 4'-deoxydoxorubicin (esorubicin): 30 mg/m2 i.v. every three weeks, with an increase to 35 mg/m2 when bone marrow toxicity was absent after the first cycle, for at least two or three cycles prior to evaluation. The 25 evaluable patients received a median number of 3 courses of esorubicin (range 1-14). Among the 9 evaluable patients with NHL, 3 (33%) obtained CR and 2 (22%) PR for an overall 55% objective response rate. Two of the patients with CR had been previously treated with doxorubicin. Duration of response was short (9, 13, 14 weeks, respectively). No response was seen in 2 patients with Mycosis Fungoides. Among the 16 evaluable patients with PCT, 2 (12.5%) obtained a response, and 4 (25%) obtained improvement. None of these patients was previously treated with doxorubicin. Toxicity according to criteria proposed by WHO was acceptable in patients with NHL, whereas it was quite severe in patients with PCT, with two deaths from septicemia during the granulocytopenic periods. Congestive heart failure and change in the left ventricular ejection fraction were not evidenced in any patient, in particular not in the patient who has been treated with 14 cycles of esorubicin for a total dose of 300 mg/m2. Although preliminary, our results have shown that esorubicin is capable of inducing a consistent proportion of objective responses in patients with NHL and PCT, even in those previously treated and resistant to doxorubicin.

UR - http://www.scopus.com/inward/record.url?scp=0023180079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023180079&partnerID=8YFLogxK

M3 - Article

C2 - 3108102

AN - SCOPUS:0023180079

VL - 72

SP - 97

EP - 99

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -